Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Quetiapine Fumarate 25 mg Tablets Under Fasting Conditions

NCT01570907 is registered in ClinicalTrials.gov with Roxane Laboratories as lead sponsor.

NCT NCT01570907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01570907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Quetiapine Fumarate 25 mg Tablets Under Fasting Conditions
Lead sponsor
Roxane Laboratories
Phase
Not applicable
Overall status
Completed
Start date
June 30, 2007
Completion date
July 31, 2007
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

treatment for bipolar i disorder